or Try an Advanced Search...

    Technical Analysis for EQ - Equillium, Inc.

    Grade Last Price % Change Price Change
    D 1.66 -4.34% -0.08
    EQ closed down 3.35 percent on Thursday, April 18, 2024, on 21 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 9
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical EQ trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction -4.34%
    Wide Bands Range Expansion -4.34%
    Oversold Stochastic Weakness -4.34%
    New Downtrend Bearish -7.54%
    Outside Day Range Expansion -7.54%
    Wide Bands Range Expansion -7.54%
    Oversold Stochastic Weakness -7.54%
    Stochastic Reached Oversold Weakness -10.54%
    Wide Bands Range Expansion -10.54%
    Oversold Stochastic Weakness -10.54%
    Older End-of-Day Signals for EQ ...

       Recent Intraday Alerts

    Alert Time
    Down 5% 30 minutes ago
    Down 3% about 2 hours ago
    Down 2 % about 3 hours ago
    60 Minute Opening Range Breakdown about 4 hours ago
    Fell Below Previous Day's Low about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    EQ Chart by TradingView
    Basic chart:

    Profile

    Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biology Immunology Immune System Clinical Development Inflammation Monoclonal Antibody Antibody Autoimmunity Glycoproteins Immune Checkpoint Inflammatory Disorders

    Is EQ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 3 Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    Apr 1 5 Stocks That More Than Doubled in Q1 With More Gains Ahead
    Apr 1 Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
    Mar 25 Equillium GAAP EPS of -$0.07, revenue of $9.2M
    Mar 25 Equillium: Q4 Earnings Insights
    Mar 25 Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
    Mar 25 Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
    Mar 22 Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
    Mar 22 Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20%
    Mar 6 Top 10 best performing biotech stocks of 2024 so far
    See more EQ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.25
    52 Week Low 0.45
    Average Volume 345,321
    200-Day Moving Average 1.10
    50-Day Moving Average 2.26
    20-Day Moving Average 2.10
    10-Day Moving Average 1.88
    Average True Range 0.25
    RSI (14) 38.27
    ADX 25.64
    +DI 12.99
    -DI 25.64
    Chandelier Exit (Long, 3 ATRs) 2.23
    Chandelier Exit (Short, 3 ATRs) 2.36
    Upper Bollinger Bands 2.71
    Lower Bollinger Band 1.50
    Percent B (%b) 0.19
    BandWidth 57.16
    MACD Line -0.14
    MACD Signal Line -0.09
    MACD Histogram -0.051
    Fundamentals Value
    Market Cap 60.76 Million
    Num Shares 35.1 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -7.86
    Price-to-Sales 1.27
    Price-to-Book 2.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.93
    Resistance 3 (R3) 1.94 1.89 1.89
    Resistance 2 (R2) 1.89 1.84 1.88 1.88
    Resistance 1 (R1) 1.81 1.81 1.79 1.80 1.87
    Pivot Point 1.76 1.76 1.75 1.75 1.76
    Support 1 (S1) 1.68 1.71 1.66 1.67 1.59
    Support 2 (S2) 1.63 1.68 1.62 1.58
    Support 3 (S3) 1.55 1.63 1.57
    Support 4 (S4) 1.54